Letter by Popa and Netea Regarding Article, “Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis”

To the Editor:

We read with great interest the article by Flammer et al, in which the authors investigated the effects of ramipril on endothelial function during rheumatoid arthritis. They concluded that ramipril is able to significantly improve endothelial function as early as 8 weeks after daily therapy has been initiated. Therefore, their findings may have a significant impact on our attempts to diminish the increased cardiovascular risk of these patients and to improve their lifespan.

However, several important aspects should be considered in the interpretation of these results. First, the concentrations of tumor necrosis factor (TNF) detected by the authors are very low but are in the range of the minimum detectable dose of TNF stated by the manufacturer. This may cause an important bias and therefore call into question the relation described by the authors between flow-mediated dilation and circulating levels of this cytokine. Second, 3 of the 11 patients included received anti-TNF agents. We have previously indicated that ELISA is unable to give a reliable TNF plasma concentration in this particular situation because it cannot distinguish between free and anti-TNF–bound TNF. Third, therapeutic TNF neutralization on its own also is able to improve endothelial function, adding to the complexity of the authors’ findings. We therefore wonder if the authors’ conclusions would be the same if these patients were excluded from the study analysis.

We believe that the authors’ findings are biased by several methodological issues that cast a shadow on the impact of their conclusions. However, we also believe that further exploration of angiotensin-converting enzyme inhibitory strategies in rheumatoid arthritis is of extreme importance to lessen the increased burden of cardiovascular disease characterizing these patients.

Disclosures

None.

Calin Popa, MD
Department of Rheumatology
Radboud University Nijmegen Medical Centre
Nijmegen, The Netherlands

Mihai G. Netea, MD, PhD
Department of General Internal Medicine
Radboud University Nijmegen Medical Centre
Nijmegen, The Netherlands

References


(Circulation. 2008;118:e690.)

© 2008 American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.108.790972
Letter by Popa and Netea Regarding Article, "Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis"
Calin Popa and Mihai G. Netea

_Circulation_. 2008;118:e690
doi: 10.1161/CIRCULATIONAHA.108.790972
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/118/19/e690

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/